BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37500626)

  • 1. Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.
    Zhou Y; Cui G; Xu H; Chun J; Yang D; Zhang Z; Yang L; Wang J; Wan M; Calvisi DF; Lin S; Chen X; Wang H
    Cell Death Dis; 2023 Jul; 14(7):476. PubMed ID: 37500626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.
    Qiao Y; Wang J; Karagoz E; Liang B; Song X; Shang R; Evert K; Xu M; Che L; Evert M; Calvisi DF; Tao J; Wang B; Monga SP; Chen X
    Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
    Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.
    Lee SA; Ladu S; Evert M; Dombrowski F; De Murtas V; Chen X; Calvisi DF
    Hepatology; 2010 Aug; 52(2):506-17. PubMed ID: 20683950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
    Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
    Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
    Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
    Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
    Wang P; Song X; Cao D; Cui K; Wang J; Utpatel K; Shang R; Wang H; Che L; Evert M; Zhao K; Calvisi DF; Chen X
    Cell Death Dis; 2020 Feb; 11(2):91. PubMed ID: 32019910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
    Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
    Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
    Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.
    Long J; Wang Y; Li M; Tong WM; Jia JD; Huang J
    Oncol Rep; 2013 Jul; 30(1):119-24. PubMed ID: 23624687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis.
    Wang C; Kang H; Yi Y; Ding Y; Wang F; Luo J; Ye M; Hong Y; Xia C; Yan J; Liu L; Liu J; Zhong Z; Zhang Z; Zhao Q; Chang Y
    J Transl Med; 2023 Dec; 21(1):919. PubMed ID: 38110956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
    Qiao Y; Xu M; Tao J; Che L; Cigliano A; Monga SP; Calvisi DF; Chen X
    BMC Cancer; 2018 Nov; 18(1):1093. PubMed ID: 30419856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X; Zhu A; Gu X; Xie G
    Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
    Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
    Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
    Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.
    Schaeffer S; Gupta B; Calatayud AL; Calderaro J; Caruso S; Hirsch TZ; Pelletier L; Zucman-Rossi J; Rebouissou S
    J Hepatol; 2023 Sep; 79(3):704-716. PubMed ID: 37201672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.